SynthesisBMC cancer2019

Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.

Huan Deng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.